SunAct Cancer Institute – Advanced Cancer Treatment & Research in India
Toll free

18002022232

CLINICAL STUDY FOR BREAST CANCER

About The Study

This study is for people with advanced breast cancer that is hormone receptor-positive (HR+) and HER2-negative, and who also have specific gene changes (mutations) in BRCA1, BRCA2, or PALB2.

Who Can Join ?

You may qualify if you:

  • Are a female patient aged 18 years or older at the time of screening

  • Have HER2-negative breast cancer

  • Have a BRCA1, BRCA2, or PALB2 gene mutation and are Hormone Receptor-Positive

Why Join ?

  • Access to advanced treatment under expert care

  • Regular monitoring and comprehensive support

  • Opportunity to contribute to breakthrough research

  • Full medical supervision throughout participation

Expanding Your Treatment Options

  1. Advanced Cellular Therapies:
    Harnessing the power of living cells to target and destroy cancer with precision treatments like CAR-T therapy.
  2. BMT / Stem Cell Transplantation:
    Rebuilding hope through bone marrow and stem cell transplants that restore your body’s ability to fight cancer.
  3. Immunotherapy:
    Empowering your own immune system to recognize and eliminate cancer cells naturally.
  4. Targeted Therapy:
    Precision medicine that attacks cancer at the molecular level while protecting healthy tissue.
  5. Chemotherapy:
    Evidence-based treatment protocols designed to eliminate cancer cells and prevent recurrence.
  6. Pediatric Services:
    Specialized care tailored to the unique needs of children and adolescents fighting cancer.

Please provide YOUR contact information only.

Eligibility will be confirmed after a medical evaluation by our study team.

All clinical research activities are conducted under expert medical supervision and ethical guidelines.

proceed to call

Share your details below, and we’ll reach out to you without delay.

Disclaimer : We will be using this information for calling purposes only.

Share your details below, and we’ll reach out to you without delay.

Disclaimer : We will be using this information for calling purposes only.

SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct head and neck cancer case study using TCR-p53 therapy in inoperable squamous cell carcinoma
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male